Daily News Podcast

Esketamine gets the green light for depression

Publish date: March 7, 2019

 

The FDA approves intranasal esketamine for refractory major depressive disorder. A behavioral intervention improves physical activity in patients with diabetes. Groups of physicians produce more accurate diagnoses than individuals. And there’s a new target for reducing sodium consumption.
Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

Recommended Reading

Pregnant women want genome guidance
MDedge Emergency Medicine
Opioids often prescribed in low-income areas
MDedge Emergency Medicine
Mediterranean diet cut Parkinson’s risk
MDedge Emergency Medicine
500 Women in Medicine: Part II
MDedge Emergency Medicine
Parental leave inequities: Kirti Magudia and Thomas Ng, Part I
MDedge Emergency Medicine
Peripheral perfusion fails septic shock test, but optimism remains
MDedge Emergency Medicine
Trump targets abortion by denying family planning funds
MDedge Emergency Medicine
Will having fewer primary care physicians shorten Americans’ lifespans?
MDedge Emergency Medicine
Cancer-battling breath, Zombie Bambi, and hops as health food
MDedge Emergency Medicine
Infective endocarditis isn’t what it used to be
MDedge Emergency Medicine